Key Market Indicators
Latvian antacid medicine sales are expected to reach $840,000 by 2026. This is an increase of 2% from the 2021 figure of $770,000. Since 2006, the Latvian market has seen average growth of 9% year on year. In 2021, the country was ranked 18th globally, with Slovakia ahead of them at $770,000. Italy, Germany and Chile were ranked second, third and fourth in the world respectively.
